Citigroup Cuts Insulet (NASDAQ:PODD) Price Target to $165.00

Insulet (NASDAQ:PODD) had its target price decreased by analysts at Citigroup from $175.00 to $165.00 in a note issued to investors on Thursday,MarketScreener reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. Citigroup’s target price would indicate a potential upside of 13.01% from the company’s previous close.

Several other research analysts have also recently weighed in on the stock. Barclays decreased their price objective on shares of Insulet from $286.00 to $198.00 and set an “underweight” rating for the company in a report on Thursday, May 7th. William Blair initiated coverage on shares of Insulet in a report on Wednesday, May 20th. They issued an “outperform” rating for the company. Wells Fargo & Company lowered their price target on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a report on Wednesday, May 6th. Truist Financial dropped their price target on shares of Insulet from $315.00 to $250.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Oppenheimer reduced their price objective on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $252.04.

Insulet Trading Down 5.1%

NASDAQ:PODD opened at $146.01 on Thursday. The company has a 50-day moving average price of $187.01 and a 200-day moving average price of $247.26. The stock has a market cap of $10.11 billion, a price-to-earnings ratio of 33.96, a P/E/G ratio of 1.22 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet has a 12 month low of $141.02 and a 12 month high of $354.88.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same period in the previous year, the firm posted $1.02 EPS. The business’s revenue for the quarter was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts predict that Insulet will post 6.43 EPS for the current year.

Institutional Investors Weigh In On Insulet

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in Insulet by 1.0% in the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after buying an additional 87,845 shares in the last quarter. State Street Corp lifted its stake in Insulet by 2.1% during the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after purchasing an additional 65,317 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Insulet by 2.1% during the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after acquiring an additional 41,019 shares during the period. Invesco Ltd. raised its holdings in shares of Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after purchasing an additional 141,167 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Insulet by 462.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock valued at $258,088,000 after buying an additional 1,011,369 shares during the last quarter.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.